$895.865
1.875[0.21%]
Last update: 12:56PM Get Real Time Here
Regeneron Pharmaceuticals
(NASDAQ:REGN)Regeneron Pharmaceuticals Stock (NASDAQ:REGN), Analyst Ratings, Price Targets, Predictions
Regeneron Pharmaceuticals Inc has a consensus price target of $897.81, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from UBS, Cantor Fitzgerald, and Cantor Fitzgerald on April 17, 2024, April 17, 2024, and April 15, 2024. With an average price target of $983 between UBS, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 7.76% upside for Regeneron Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
UBS
Cantor Fitzgerald
Cantor Fitzgerald
B of A Securities
RBC Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Regeneron Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 20.47% | UBS | Colin Bristow | $1090 → $1099 | Maintains | Buy | Get Alert |
| 04/17/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 1.4% | Cantor Fitzgerald | Olivia Brayer | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/15/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 1.4% | Cantor Fitzgerald | Louise Chen | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/12/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | -21.07% | B of A Securities | Geoff Meacham | $710 → $720 | Maintains | Underperform | Get Alert |
| 04/09/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 30.34% | RBC Capital | Brian Abrahams | → $1189 | Reiterates | Outperform → Outperform | Get Alert |
| 04/03/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 24.42% | Truist Securities | Robyn Karnauskas | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/26/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 24.42% | Truist Securities | Robyn Karnauskas | $1135 → $1135 | Maintains | Buy | Get Alert |
| 03/13/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 22.23% | Morgan Stanley | Matthew Harrison | $1104 → $1115 | Maintains | Overweight | Get Alert |
| 03/12/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 23.32% | Bernstein | William Pickering | → $1125 | Initiates | → Outperform | Get Alert |
| 03/11/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 23.32% | Bernstein | Aaron Gal | → $1125 | Initiates | → Outperform | Get Alert |
| 02/27/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 29.79% | RBC Capital | Brian Abrahams | $1096 → $1184 | Maintains | Outperform | Get Alert |
| 02/06/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 1.4% | Cantor Fitzgerald | Olivia Brayer | $850 → $925 | Maintains | Neutral | Get Alert |
| 02/05/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 21.68% | RBC Capital | Brian Abrahams | $1076 → $1110 | Maintains | Outperform | Get Alert |
| 02/05/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 18.61% | BMO Capital | Evan David Seigerman | $1055 → $1082 | Maintains | Outperform | Get Alert |
| 01/29/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 17.95% | RBC Capital | Brian Abrahams | → $1076 | Reiterates | Outperform → Outperform | Get Alert |
| 01/23/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 11.81% | Barclays | Carter Gould | $935 → $1020 | Maintains | Overweight | Get Alert |
| 01/12/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 17.95% | RBC Capital | Brian Abrahams | → $1076 | Upgrade | Sector Perform → Outperform | Get Alert |
| 01/09/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | -6.82% | Cantor Fitzgerald | Olivia Brayer | → $850 | Reiterates | Neutral → Neutral | Get Alert |
| 12/18/2023 | REGN | Buy Now | Regeneron Pharmaceuticals | $912.25 | 14.55% | Truist Securities | Robyn Karnauskas | → $1045 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Regeneron Pharmaceuticals (REGN)?
The latest price target for Regeneron Pharmaceuticals (NASDAQ: REGN) was reported by UBS on April 17, 2024. The analyst firm set a price target for $1099.00 expecting REGN to rise to within 12 months (a possible 22.67% upside). 67 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Regeneron Pharmaceuticals (REGN)?
The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ: REGN) was provided by UBS, and Regeneron Pharmaceuticals maintained their buy rating.
When was the last upgrade for Regeneron Pharmaceuticals (REGN)?
The last upgrade for Regeneron Pharmaceuticals Inc happened on January 12, 2024 when RBC Capital raised their price target to $1076. RBC Capital previously had a sector perform for Regeneron Pharmaceuticals Inc.
When was the last downgrade for Regeneron Pharmaceuticals (REGN)?
The last downgrade for Regeneron Pharmaceuticals Inc happened on June 28, 2023 when Canaccord Genuity changed their price target from $953 to $720 for Regeneron Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Regeneron Pharmaceuticals (REGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Regeneron Pharmaceuticals (REGN) correct?
While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a maintained with a price target of $1090.00 to $1099.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $895.87, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.